Investors pile into psychedelic drug startups tackling mental health

I had a conversation with a recruiter for one of these startups a few months ago during a job search. I was initially quite interested, this company made an app for researchers and clinicians to help guide people through the ketamine experience. Me: “That’s interesting, you guys must be partnering with academics and researchers on grants and stuff for money right?” Them: “Nope we make money by selling data on the patients”

There’s nothing here for startups is there?

Also Silicon Valley startups have the least trustworthy reputation.

Firstly, the commodification of mental health treatments raises questions about access and equity. If the primary driver behind the development of these therapies is profit, there’s a risk that only those who can afford them will benefit, potentially exacerbating existing disparities in mental health care.

Secondly, while psychedelic drugs offer promising therapeutic potential, their promotion must be approached with caution to avoid oversimplification of complex mental health issues. Mental health is multifaceted, involving biological, psychological, and social factors, and no single treatment is a panacea. Ensuring that these substances are integrated into comprehensive care models that address the broader needs of individuals is essential.

Moreover, the normalization of psychedelic drug use for therapeutic purposes can blur the lines between medical treatment and recreational use, raising concerns about misuse, addiction, and the stigmatization of those who choose not to use these treatments.